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SUMOylation is a dynamic process, catalyzed
by SUMO-specific ligases and reversed by Sen-
trin/SUMO-specific proteases (SENPs). The
physiologic consequences of SUMOylation
and deSUMOylation are not fully understood.
Here we investigate the phenotypes of mice
lacking SENP1 and find that SENP1/ embryos
show severe fetal anemia stemming from defi-
cient erythropoietin (Epo) production and die
midgestation. We determine that SENP1 con-
trols Epo production by regulating the stability
of hypoxia-inducible factor 1a (HIF1a) during
hypoxia. Hypoxia induces SUMOylation of HIF1a,
which promotes its binding to a ubiquitin
ligase, von Hippel-Lindau (VHL) protein, through
a proline hydroxylation-independent mecha-
nism, leading to its ubiquitination and degra-
dation. In SENP1/ MEFs, hypoxia-induced
transcription of HIF1a-dependent genes such
as vascular endothelial growth factor (VEGF)
and glucose transporter 1 (Glut-1) is markedly
reduced. These results show that SENP1 plays
a key role in the regulation of the hypoxic
response through regulation of HIF1a stability
and that SUMOylation can serve as a direct
signal for ubiquitin-dependent degradation.
INTRODUCTION
Conjugation of small ubiquitin-related modifier protein
(SUMO) to a large number of substrates has been sug-
gested to regulate numerous cellular processes from
yeast to mammal (Hay, 2005; Yeh et al., 2000). Most
SUMO targets are in the nucleus; they include transcrip-
tion factors, transcriptional coregulators, and chromo-
some-remodeling regulators (Gill, 2004). SUMOylation of584 Cell 131, 584–595, November 2, 2007 ª2007 Elsevier Inc.these proteins can alter their cellular localization and bio-
logical activity.
SUMO conjugation is a dynamic process, in that it can
be readily reversed by a family of Sentrin/SUMO-specific
proteases (SENPs) (Hay, 2005; Yeh et al., 2000). Six
SENPs have been identified in human, each with different
cellular location and substrate specificity (Yeh et al.,
2000). They can be divided into three subfamilies on the
basis of their sequence homology, cellular location, and
substrate specificity. The first subfamily consists of
SENP1 and SENP2, which have broad substrate specific-
ity. The second subfamily consists of SENP3 and SENP5,
both of which are nucleolar proteins with preferences for
SUMO-2/3 (Di Bacco et al., 2006; Gong and Yeh, 2006).
The third subfamily consists of SENP6 and SENP7, which
have an extra loop in their catalytic domains. Although
SENPs are known to reverse SUMOylation in many
different systems, their physiological role has not been
precisely defined.
SENP1, a nuclear SUMO protease, has been shown to
regulate androgen receptor transactivation by targeting
histone deacetylase 1 and to induce c-Jun activity through
deSUMOylation of p300 (Cheng et al., 2004, 2005). Yama-
guchi et al. studied mice derived from an ES cell line with
a retroviral vector that had been randomly inserted into the
enhancer region on the SENP1 gene. This random inser-
tion reduced expression of the SENP1 transcript, causing
the mice to die between E12.5 and E14.5 (Yamaguchi
et al., 2005). Although no specific histological abnormali-
ties were found in the E13.5 embryos, there was a hint
of an abnormality in the development of blood vessels in
the placenta. Thus, it remains unclear howSENP1 contrib-
utes to normal development.
Therefore, we generated SENP1 knockout mice to de-
lineate the contribution of SENP1 in development. Inacti-
vation of the SENP1 gene causes severe fetal anemia in
midgestation as a result of deficient Epo production.
Epo is essential for growth and survival of erythroid pro-
genitors during differentiation into red cells (Wu et al.,
1995). We found that SENP1 controls Epo production by
regulating the stability of hypoxia-inducible factor 1a
(HIF1a). Hypoxia induces HIF1a SUMOylation, which
promotes HIF1a degradation through a VHL- and pro-
teasome-dependent mechanism. SENP1 deconjugates
SUMOylated HIF1a and allows HIF1a to escape
degradation during hypoxia. These results reveal an
important physiological role of SENP1 in the hypoxic
response through regulation of HIF1a stability and that
SUMOylation can also target a protein for ubiquitination
and degradation.
RESULTS
Generation of SENP1 Knockout Mice
To generate SENP1 knockout mice, a gene-trapped vec-
tor was inserted into the mouse SENP1 open reading
frame at codon 310 (Figure S1A). Specifically, the inserted
b-geo (b-galactosidase/neomycin-resistance fusion pro-
tein) was fused into the N terminus of SENP1 at codon
310 to generate SENP1 (1-309)-b-geo fusion protein,
which lacks the C-terminal catalytic domain of SENP1
(Figure S1A). This disruption was confirmed by the ab-
sence of transcripts that encode the catalytic domain of
SENP1 in SENP1/ embryos (Figure S1B). The overall
SUMOylation pattern in lysates of embryos revealed an in-
crease in high-molecular-weight SUMO-1 and SUMO-2/3
conjugates in SENP1/ embryos in comparison with
wild-type or SENP1+/ embryos (Figure S1C). In addition,
processing of the C terminus of SUMO-1 but not SUMO-2/
3 appeared to be decreased in SENP1/ embryos
(Figure S1C). These results indicate that disruption of the
SENP1 locus reduced deSUMOylation in SENP1/ em-
bryos.
Severe Anemia in SENP1/ Embryos
Heterozygous mice carrying the inactivated SENP1 gene
appeared normal and fertile. However, no live SENP1/
mice were found among offsprings of SENP1+/ inter-
crosses, indicating that the SENP1/ mutation leads to
embryonic lethality. Examination of SENP1/ embryos
at different stages of development revealed that themajor-
ity died between days 13 and 15 of gestation (Figure 1A).
The SENP1/ embryos appeared paler and smaller than
their wild-type or SENP1+/ littermates (Figure 1B). The
most dramatic morphological abnormality of these
SENP1/ embryos was severe fetal anemia. In particular,
SENP1/ embryos had more than 75% fewer erythro-
cytes than their wild-type or SENP1+/ littermates at
E15.5 (Figure 1C).
Defective Definitive Erythropoiesis in SENP1/
Embryos
During normal murine development, erythropoiesis is initi-
ated in the yolk sac at around E8 (primitive erythropoiesis),
and then it is initiated in the aorta-gonadmesonephros
(AGM) region. Atmidgestation, fetal liver becomes thema-
jor hematopoietic organ with hematopoietic activity start-
ing around E11.0 to E12.5 until 1 week postnatal (definitive
erythropoiesis) (Godin and Cumano, 2002). Because ane-mia was observed after E13.5 in SENP1/ embryos, we
reasoned that these embryos likely had a defect in defin-
itive erythropoiesis. Indeed, the number of nucleated
cells in the fetal livers of SENP1/ embryos wasmarkedly
decreased compared to their wild-type littermates
(Figure 1D). Histological examination of fetal liver sections
also revealed a marked decrease in the number of eryth-
ropoietic foci in SENP1/ embryos compared with their
wild-type littermates (Figure 1E).
Increased Apoptosis in Erythroid Precursors
of SENP1/ Embryos
We next examined hematopoiesis in the fetal livers of both
wild-type and SENP1/ embryos at E13.5 by flow cytom-
etry using markers, including CD34, CD44, c-kit, and Ter-
119, characteristic of different types of hematopoietic
cells and developmental stages (Kondo et al., 2003;
Neubauer et al., 1998). There was no significant difference
between SENP1/ embryos and wild-type littermates,
except that the population of Ter-119+, which denotes
committed erythropoietic precursors, was markedly re-
duced in SENP1/ fetal livers (Figure S2A). These data
suggest that erythropoiesis was abnormal in SENP1/
embryos as a result of a defect in erythroid differentiation.
To determine at which stage of erythroid differentiation
SENP1 plays a crucial role, we compared the abilities of
cells derived from wild-type and SENP1/ E13.5 fetal
livers to form erythroid colony-forming units (CFU-e) and
more immature erythroid burst-forming units (BFU-e)
(Wu et al., 1995). Although fetal livers from SENP1/ em-
bryos contained erythroid progenitors, the relative number
of CFU-e arising from SENP1/ fetal liver was over 40%
smaller than that from wild-type fetal liver (Figure 2A).
However, there was no significant difference in the num-
bers of the BFU-e between SENP1/ and wild-type fetal
livers (Figure 2A). Additionally, we observed no significant
difference in the number of colony-forming unit granulo-
cyte-macrophage (CFU-GM) and pluripotent hematopoi-
etic stem cells (CFU-GEMM) between SENP1/ and
wild-type fetal livers (Figure S2B). These results indicate
that a developmental defect in CFU-e is a prominent fea-
ture in the SENP1/ embryo.
The reduced ratio of CFU-e to BFU-e progenitors and
the decrease in the number of Ter-119+ erythroid cell sug-
gested a reduction in the net growth ofSENP1/ erythroid
progenitors resulting from either decreased cell prolifera-
tion or increased apoptosis. No differences were observed
in the proliferation of fetal liver cells between SENP1/
embryos and their wild-type littermates, as shown by Ki-
67 staining (upper panel, Figure S2C). However, TUNEL
staining showed that the number of TUNEL-positive cells
wasmuch greater in the liver sections from SENP1/ em-
bryos than in those of their wild-type littermates (lower
panel, Figure S2C). To validate further, we stained fetal
liver cells with the anti-Ter-119 antibody and then analyzed
cells by flow cytometry. This showed that the percentage
of Ter-119-positive cells was decreased in SENP/ em-
bryos, from 81% in E13.5 wild-type fetal livers to 37% inCell 131, 584–595, November 2, 2007 ª2007 Elsevier Inc. 585
Figure 1. Severe Anemia in SENP1/
Embryos
(A) The ratios of the observed live and dead (in
parentheses) SENP1/ embryos to the total
number of embryos analyzed at different
stages of embryonic development.
(B) Appearance of SENP1+/+ and SENP1/
embryos at E15.5. The SENP1/ embryo
and yolk sac were paler and smaller than those
of the wild-type embryo and appeared to con-
tain fewer red blood cells in major blood ves-
sels.
(C) Relative numbers of red blood cells in pe-
ripheral blood in E15.5 wild-type (+/+, n = 5),
heterozygote (+/, n = 9), and SENP1 (/,
n = 4) embryos. Results shown are means ±
standard deviation (SD). A significant decrease
in the number of red blood cells was found in
SENP1 (/) embryos (p < 0.007) when com-
pared with those in wild-type or heterozygote
embryos.
(D) Total number of nucleated cells per fetal
liver in E13.5 (+/+, n = 4; /, n = 3), E14.5
(+/+, n = 4; /, n = 4), and E15.5 embryos
(+/+, n = 5; /, n = 3). Results shown are
means ± SD. Significant differences between
wild-type and mutant embryos were found at
E14.5 (p < 0.015) and E15.5 (p < 0.004).
(E) Hematoxylin- and Eosin-stained sections of
fetal liver from E12.5 SENP1+/+ and / em-
bryos. The SENP1/ fetal liver showed
a marked decrease in the number of erythro-
poietic foci and increase in apoptotic cells.their SENP1/ littermates (data not shown). Among the
Ter-119-positive cells, about 34.5% of SENP1/ cells
were stained by TUNEL; in contrast, few TUNEL-positive
cells (1.9%) were observed from the wild-type liver
(Figure 2B). These results suggested that the erythroid
cells in fetal liver were more apoptotic in SENP1/ em-
bryos than in their wild-type counterparts, which accounts
for the decrease in CFU-e progenitors, smaller fetal liver
size, and anemia in SENP1/ embryos.
Epo Production Is Reduced in SENP1/
Fetal Liver
The hematopoietic defect in SENP1/ embryos de-
scribed above was similar to that observed in Epo/ em-
bryos or in embryos with mutation of the genes critical to
the Epo signaling pathway (Neubauer et al., 1998; Parga-
nas et al., 1998; Socolovsky et al., 1999; Wu et al., 1995).
Since fetal liver erythroid progenitors depend on Epo for
growth and survival during terminal differentiation into
red blood cells (Wu et al., 1995), we reasoned that the in-
creased apoptosis of erythroid cells inSENP1/ fetal liver
could be due to either a defect in Epo production or block-586 Cell 131, 584–595, November 2, 2007 ª2007 Elsevier Inc.age in the Epo signaling pathway. To assess these possi-
bilities, we first examined the expression of genes in-
volved in the Epo signaling pathway (specifically, EpoR,
Jak2, and STAT5) and other growth factors associated
with erythroid progenitors in fetal livers. A dramatic reduc-
tion in the level of Epo mRNA expression was shown in
SENP1/ fetal livers (Figure 2C). In contrast, the expres-
sion of EpoR, Jak2, STAT5, and growth factors c-kit and
SCF was not significantly different between SENP1/
and wild-type fetal livers (Figure 2C). The reduced Epo
expression in E12.5 fetal liver cells of SENP1/ embryos
was further confirmed by immunohistochemistry (Fig-
ure 2D). These results demonstrated that Epo production
was significantly reduced in SENP1/ fetal livers.
Epo Prevents Apoptosis of SENP1/
Fetal Liver Cells
To determine whether apoptosis of cells in the fetal livers
of SENP1/ embryos was caused by a deficiency in Epo
production, we examined the ability of Epo to prevent
apoptosis of the erythroid progenitors from SENP1/
fetal liver. As shown by rates of apoptosis in vitro, E13.5
Figure 2. SENP1/ Erythroid Progeni-
tors Undergo Apoptosis due to Epo Defi-
ciency
(A) Analysis of CFU-e- and BFU-e-forming abil-
ity of fetal liver cells from E13.5 SENP1+/+ and
SENP1/ embryos. Results shown are means
± SD determined from three embryos. The
number of CFU-e from liver cells of SENP1/
embryos was significantly less than that from
SENP1+/+ embryos (p < 0.05).
(B) Liver cells isolated from E13.5 SENP1+/+
and SENP1/ embryos were stained with
Ter-119 antibody and analyzed by the TUNEL
procedure. Histograms show TUNEL staining
profile of the Ter-119-positive population iden-
tified by flow cytometry. The percentages in
the histograms are the percentages of TU-
NEL-positive cells.
(C) RT–PCR analysis of a variety of genes that
are involved in erythroid differentiation in fetal
livers of SENP1+/+ and SENP1/ embryos at
E11.5. Samples were amplified for 36, 39,
and 42 cycles for Epo; 25, 28, and 32 cycles
for EpoR, c-kit, SCF, Jak2, and STAT5. b-Actin
mRNA levels (amplified for 18, 21, and 24 cy-
cles) were measured as control.
(D) Fetal liver sections from E12.5 SENP1+/+
and SENP1/ embryos were stained with
anti-Epo antibody (brown).
(E and F) Fetal liver cells isolated from E13.5
SENP1+/+ and SENP1/ embryos were cul-
tured for 24 hr in the absence or presence of
Epo (5 U/ml). Cell numbers were counted un-
der microscope (E). Results shown in (E) are
means ± SD determined from three embryos.
TUNEL-positive cells were quantitated by
flow cytometry. Percentages in histograms
are the percentages of TUNEL-positive cells
(F).wild-type fetal liver cells, which were grown in a medium
lacking Epo, showed a reduction in cell number and in-
crease in apoptosis similar to those observed in fetal liver
cells of their SENP1/ littermates. Addition of Epo to the
culture medium prevented reduction in cell number and
apoptosis in SENP1/ fetal liver cells similar to their
wild-type littermates (Figures 2E and 2F). These results
demonstrated that the increased apoptosis of erythroid
progenitors was due to deficiency in Epo production in
SENP1/ fetal liver.
SENP1 Regulates Epo Transcription through
HIF1a
The Epo gene is expressed primarily in fetal liver and adult
kidney and is regulated in response to oxygen availability
(Ebert and Bunn, 1999). Since SENP1 is expressed in
mouse fetal liver atmidgestation stage (Figure S3), we rea-
soned that SENP1 might directly regulate Epo expression
in fetal liver. A hepatoma cell line, Hep 3B, was used to de-
termine whether SENP1 regulated Epo production. Two
SENP1-specific siRNAs were able to efficiently knock
down SENP1 expression (Figure S4) and significantly re-
duced Epo expression in Hep 3B cells in response to treat-ment with hypoxia (Figure 3A), indicating that SENP1
played an important role in Epo production under the hyp-
oxia condition.
Since SENP1 regulates the transcription of numerous
genes by targeting transcription factors or coregulators
(Cheng et al., 2004, 2005), we next examined whether
Epo transcription was also regulated by SENP1. In this
study, the luciferase reporter gene driven by the Epo pro-
moter plus enhancer (Epo-Luc) was transfected into Hep
3B cells with SENP1 or SENP1 catalytic inactive mutant
(SENP1m), in which a conserved amino acid, cysteine
603, in the catalytic domain of SENP1 was substituted
with alanine. In the presence of hypoxia, SENP1, but not
the SENP1 mutant, significantly induced Epo reporter
gene transcription (Figure 3B), suggesting that SENP1
regulated Epo transcription and the regulation required
the deSUMOylation activity of SENP1. Interestingly, with-
out hypoxia treatment, SENP1 had only marginal effect on
Epo transcription.
Since HIF1a is a major transcription factor for hypoxia-
regulated Epo expression (Giaccia et al., 2004), we asked
whether HIF1a was required for SENP1-regulated Epo
transcription. Coexpression of SENP1markedly enhancedCell 131, 584–595, November 2, 2007 ª2007 Elsevier Inc. 587
Figure 3. SENP1 Regulates Epo Produc-
tion through HIF1a
(A) ELISA analysis of Epo production in Hep 3B
cells. Data are presented as means ± SD of the
results of three independent experiments for
Figures 3A, 3B, 3C, and 3D. (NS = nonspecific
siRNA).
(B) SENP1 enhanced Epo transcription in-
duced by hypoxia. The indicated reporter
gene, HIF1a, and SENP1 expression plasmids
were cotransfected into Hep 3B cells. The cells
were treated with hypoxia (1%O2) for 12 hr be-
fore luciferase assay. The Epo reporter gene
with mutation of HIF1a-binding sites on the
Epo enhancer is indicated by mEpo-Luc.
SENP1m is the catalytically inactive SENP1.
(C) SENP1 enhanced HIF1a-dependent Epo
transcription. The indicated reporter gene,
HIF1a, and SENP1 expression plasmids were
cotransfected into Hep 3B cells.
(D) SENP1 was essential for HIF1a-dependent
Epo transcription. Epo-Luc and the indicated
siRNA expression plasmids were cotrans-
fected into Hep 3B cells without or with HIF1a
plasmids.HIF1a-dependent Epo transcription (Figure 3C). However,
mutation of HIF1a-binding sites on the Epo enhancer
(mEpo-Luc) completely abolished SENP1 activity (Fig-
ure 3C). Furthermore, silencing of endogenous SENP1
expression in Hep 3B cells using SENP1 siRNA (SENP1-
si1 and SENP1-si2) also reduced Epo transcription in
response to HIF1a by 80% (Figure 3D). These results
strongly suggested that Epo expression was regulated
by SENP1 through its regulation of HIF1a activity.
SENP1 Is Essential for Ensuring HIF1a Stability
during Hypoxia
It is well-known that regulation of HIF1a occurs mostly at
the protein level. In SENP1/ mice, HIF1a protein level
was significantly decreased in a section of the SENP1/
fetal liver compared with the SENP1+/+ littermate
(Figure 4A). However, HIF1a mRNA levels in fetal livers
of SENP1/ or wild-type embryos were similar, suggest-
ing that the decrease in HIF1a protein level resulted from
protein degradation but not a reduction of HIF1a tran-
scription in SENP1/ embryos (Figure S5).
HIF1a is degraded by a proteasome-dependent mech-
anism under normoxia (Huang et al., 1998; Maxwell et al.,
1999;Wang et al., 1995). Hypoxia was believed to stabilize
HIF1a protein and therefore increased its activity (Giaccia
et al., 2004; Huang et al., 1998; Maxwell et al., 1999). We
hypothesized that regulation of HIF1a protein to hypoxia
was defective in SENP1/ cells. To test this possibility,
we determined changes in HIF1a protein level in
SENP1/ and wild-type MEF cells when exposed to hyp-
oxia. As shown in Figure 4B, hypoxia markedly increased
the protein level of HIF1a in the wild-type MEF cells, but
the increase was much less in the SENP1/ MEF cells.588 Cell 131, 584–595, November 2, 2007 ª2007 Elsevier Inc.Furthermore, the half-life of HIF1a protein was markedly
reduced in the SENP1/ MEF cells under the hypoxia
condition in a pulse-chase experiment (Figure 4C). Nor-
moxia-induced HIF1a degradation is dependent on its in-
ternal oxygen-depend-degradation (ODD) domain (Huang
et al., 1998). We then determined whether the ODD do-
main was a direct target of SENP1 regulation of HIF1a sta-
bility under hypoxia condition. We used the HIF1a ODD
domain (344-698) fused Gal4 (pG4-ODD-VP16), which
was previously demonstrated to have normoxic- and
VHL-dependent degradation and activity (Huang et al.,
1998; Maxwell et al., 1999). Indeed, coexpression of
SENP1 markedly enhanced hypoxia-induced ODD activ-
ity. However, hypoxia-induced activity of the ODD domain
was completely abolished by SENP1-siRNA (Figure 4D).
These results strongly indicated that SENP1 was essential
for HIF1a stabilization under hypoxia condition.
Consistent with the decrease in HIF1a expression dur-
ing hypoxia, HIF1a activity was also significantly reduced
in SENP1/ MEF cells as measured by the response of
the HRE-luciferase reporter gene to hypoxia in SENP1/
and wild-type MEF cells (Figure 4E). As HIF1a is a major
transcription factor in the regulation of a large number of
hypoxia-inducible genes, we also showed that hypoxia-in-
duced transcription of VEGF and Glut-1 genes was dra-
matically decreased in SENP1/ MEF cells (Figure 4F).
This defect was similar to the response of HIF1a/ ES
upon hypoxia exposure (Iyer et al., 1998; Ryan et al.,
1998). We further confirmed that this defect in SENP1/
MEF cells was mediated by HIF1a, as transfected HI-
F1aSM (SUMOylation mutant) could restore hypoxia-in-
duced expression of the VEGF gene in the transfected
cells (Figure 4G). These results indicated that SENP1
Figure 4. Defect inHypoxia-Induced Sta-
bilization of HIF1a in SENP1/ Embryos
(A) HIF1a expression was decreased in
SENP1/ fetal liver. Fetal liver sections from
E12.5 SENP1+/+ and SENP1/ embryos
were stained with anti-HIF1a antibody (brown).
(B) Hypoxia-induced HIF1a protein expression
was decreased in SENP1/ MEF cells.
SENP1+/+ and / MEF cells were treated
with hypoxia (1% O2) for 3 hr before harvest.
The whole-cell lysate (WCL) was analyzed by
western blotting with anti-HIF1a and actin anti-
bodies.
(C) The half-life of HIF1a protein under hypoxia
was decreased in SENP1/ MEF cells.
(D) SENP1 was essential for hypoxia-induced
HIF1a ODD(344–698) activity. 293 cells were
transfected with pGal4-VP16 or pGal4-
ODD(344–698)-VP16 plus other plasmids as in-
dicated. Cells were incubated for 12 hr in nor-
moxia or hypoxia (1% O2) before harvest. The
data are presented as the corrected (by internal
control) pGal4-ODD-VP16 luciferase activity
that normalized to the counts of pGal4-VP16.
(E) Hypoxia-induced HIF1a activity was signifi-
cantly reduced in SENP1/ MEF cells. Data
are presented asmeans ± SD of three indepen-
dent experiments.
(F) Hypoxia-induced expression of VEGF and
Glut-1 was reduced in SENP1/ MEF cells.
Expression of VEGF, Glut-1, and Actin-b was
determined in SENP1+/+ or / MEF cells by
RT-PCR.
(G) HIF1a restored hypoxia-induced expres-
sion of VEGF in SENP1/ MEF cells.
SENP1/ MEF cells were transfected with
HIF1a SM (SUMOylationmutant) or vector con-
trol plasmids and treated with hypoxia (1% O2)
for different times as indicated. Expression of
VEGF and Actin-bwas determined by RT-PCR.played a critical role in regulating the stability and activity
of HIF1a protein during hypoxia.
SUMOylated HIF1a Is Degraded in a Proteasome-
Dependent Manner
Since SENP1 could deSUMOylate HIF1a, SENP1 might
be directly responsible for the decrease in HIF1a activity
and stability in the SENP1/ embryo (Figures 5A and
S6). The effect of deSUMOylation on HIF1a activity was
directly confirmed by using HIF1a SUMOylated site mu-
tants: K391R, K477R, and K391/477R (SM) (Bae et al.,
2004). As shown in Figure 5B, mutation of the two
SUMOylation sites of HIF1a (SM) significantly increased
the transcriptional activity of HIF1a and also reduced the
ability of SENP1 to enhance HIF1a-dependent Epo tran-
scription. Furthermore, hypoxia-induced accumulation of
SUMOylated HIF1a only occurred in SENP1/ MEF cells
but not in wild-type cells (Figure 5C). Interestingly, this ac-
cumulation did not appear in SENP2/ MEF cells
(Figure S7), suggesting that SENP1 specifically targeted
HIF1a for deSUMOylation (Figure 5C).The simultaneous accumulation of SUMOylated HIF1a
and the decrease in HIF1a stability in SENP1/ cells dur-
ing hypoxia prompted us to study whether SUMOylation
might lead to HIF1a degradation. Indeed, SUMOylated
bands of HIF1a resulted from coexpression of HIF1a
and HA-SUMO-1 and were difficult to detect in the ab-
sence of a proteasome inhibitorMG132 but readily detect-
able when both SENP1 siRNA and MG132 were used
(Figure 5D). These results were further confirmed by ex-
amining endogenous HIF1a in SENP1/ and wild-type
MEF cells with exposure to both hypoxia and MG132.
As expected, hypoxia-induced SUMOylated HIF1a was
readily detected in SENP1/ MEF but not in wild-type
MEF cells. Furthermore, MG132 treatment markedly in-
creased hypoxia-induced SUMOylated bands of HIF1a
in SENP1/ MEF cells, suggesting that the level of
SUMOylated HIF1a was controlled by a proteasome-de-
pendent mechanism (Figure 5E, upper panel). Meanwhile,
HIF1a protein level was significantly increased in SENP1
wild-type MEF cells but not in the SENP1/ MEF cells
with exposure to hypoxia (Figure 5E, lower panel). Taken
together, these results suggested that SUMOylatedCell 131, 584–595, November 2, 2007 ª2007 Elsevier Inc. 589
Figure 5. SUMOylated HIF1a Accu-
mulates in SENP1/ MEF Cells and
Undergoes Proteasomal-Dependent
Degradation under Hypoxia
(A) SENP1 deconjugated SUMOylated HIF1a in
vitro. SUMOylated GST-ODD(344–698) PM re-
combinant protein was produced by in vitro
SUMOylation. Flag-SENP1 or SENP1m was
generated by in vitro translation. SUMOylated
GST-ODDPM and SENP1 (or SENP1m) were
incubated for 1 hr at 37C. The reaction mix-
tures were detected by western blot with anti-
HIF1a (left panel), anti-SUMO-1 (right panel),
and anti-Flag antibodies (bottom panel).
(B) Mutation of SUMOylation sites increased
HIF1a-dependent Epo transcription and re-
duced HIF1a response to SENP1. Epo-Luc
and the indicated plasmids were cotransfected
into Hep 3B cells. Data are presented asmeans
± SD of three independent experiments.
(C) SUMOylated HIF1a accumulated in
SENP1/ MEF cells but not in wild-type or
SENP2/MEF cells after exposure to hypoxia.
Wild-type (+/+), SENP1/, or SENP2/ MEF
cells were treated with or without hypoxia (1%
O2) for 4 hr as indicated. HIF1a was immuno-
precipitated with anti-HIF1a antibody from
these cell lysates. The precipitates were immu-
noblotted (IB) with anti-SUMO-1 antibody (top
panel). Asterisk indicates IgG band.
(D) SUMOylated HIF1a level was controlled by
SENP1 and proteasome-dependent degrada-
tion. COS-7 cells were transfected with indi-
cated plasmids and then treated without or
with MG132 (10 mM) for 4 hr before harvesting
and immunoprecipitated with anti-HIF1a (IP).
Bound proteins were detected by anti-HA and
anti-HIF1a immunoblotting (IB). WCLswere im-
munoblotted (IB) with anti-HA. Asterisk indi-
cates IgG band.
(E) SUMOylated HIF1a accumulated in SENP1/MEF cells after exposure to hypoxia and underwent proteasome-dependent degradation. SENP1+/+
or / MEF cells were treated by hypoxia (1% O2) and MG132 (10 mM) for 4 hr as indicated. HIF1a was immunoprecipitated with anti-HIF1a antibody
from cell lysates. The precipitates were immunoblotted (IB) with anti-SUMO-1 and -HIF1a antibodies. Asterisk indicates IgG band.HIF1awas degraded in a proteasome-dependent manner
during hypoxia in the absence of SENP1.
Degradation of SUMOylated HIF1a Is Dependent
on VHL
The above results suggest that SUMO and SENP1 might
regulate ubiquitination of HIF1a. As shown in Figure 6A,
ubiquitination of HIF1a was significantly increased when
SUMO-1 was overexpressed (lane 3 versus lane 2 in
Figure 6A). In contrast, cotransfection of SENP1, but not
SENP1 mutant, significantly decreased ubiquitination of
HIF1a (lanes 4 and 5 versus 2 in Figure 6A). We asked
whether VHL, a well-known E3 ligase for HIF1a ubiquitina-
tion (Ivan et al., 2001; Jaakkola et al., 2001; Maxwell et al.,
1999; Ohh et al., 2000), could also serve as an E3 ligase for
SUMOylated HIF1a. To address this possibility, we first
examined hypoxia-induced SUMOylation of HIF1a in
RCC4 (renal cancer cells with inactivated VHL) and
RCC4/VHL (VHL-restored RCC4 cells) (Maxwell et al.,590 Cell 131, 584–595, November 2, 2007 ª2007 Elsevier Inc.1999). SUMOylated HIF1a was easily detected in VHL
null RCC4 cells even without MG132 treatment (lane 2 ver-
sus 3 in top panel, Figure 6B). In contrast, this band was
only weakly detectable in RCC4/VHL cells exposed to
hypoxia and MG132 treatment. Consistent with other re-
ports, hypoxia-induced increase in HIF1a protein was
only observed in VHL-restored RCC4 cells (bottom
panel, Figure 6B). These results suggested that SUMOy-
lated HIF1a was degraded through a VHL-dependent
mechanism.
SUMO Provides an Alternative Signal for HIF1a
to Bind to VHL
We further speculated that SUMOylation serves as an al-
ternative signal for HIF1a to bind to VHL during the hyp-
oxic condition. The interaction of SUMOylated HIF1a
and VHL in vivo was examined first by using a HIF1a pro-
line residue 402/564 mutant (PM), which would decrease
background binding that resulted from hydroxylation of
Figure 6. VHL Is Required for Degrada-
tion of SUMOylated HIF1a
(A) HIF1a ubiquitination was regulated by
SUMO-1 and SENP1. COS-7 cells were co-
transfected with indicated plasmids and
treated with MG132 (10 mM) for 9 hr before har-
vesting. HIF1a was immunoprecipitated with
anti-HIF1a (IP) and bound proteins were de-
tected by anti-HA (top panel), anti-Myc (sec-
ond panel), and anti-HIF1a immunoblotting
(third panel) (IB). WCL were immunoblotted
(IB) with anti-HA (fourth panel) or anti-Flag (bot-
tom panel) antibodies. Asterisk indicates IgG
band.
(B) RCC4 or RCC4/VHL cells were treated by
hypoxia (1% O2) and/or MG132 (10 mM) for
4 hr as indicated. HIF1a was immunoprecipi-
tated with anti-HIF1a antibody from cell
lysates. The precipitates were IB with anti-
SUMO-1 or -HIF1a antibodies. Asterisk indi-
cates IgG band.
(C) VHL bound to SUMOylated HIF1a proline
mutant (HIF1aPM) in vivo. COS-7 cells were
cotransfected with indicated plasmids and
treated without or with MG132 (10 mM) for
4 hr before harvesting. VHL was immunopre-
cipitated with anti-Flag (IP) from the nuclear
fraction of the transfected cells and bound pro-
teins were detected by anti-HIF1a (top panel),
anti-HA (second panel), or anti-Flag immuno-
blotting (third panel) (IB). HIF1awas also immu-
noprecipitated with anti-HIF1a (IP) from the
nuclear fraction of transfected cells and bound
proteins were detected by anti-HA antibody
(IB) (fourth panel). WCL were IB with anti-
HIF1a (bottom panel). Asterisk indicates IgG
band.
(D) VHL specifically bound to SUMOylated
HIF1a ODD with proline mutation (GST-
ODD[344–698] PM) in vitro. GST-ODD(344–
698) PM recombinant protein and SUMOylated
GST-ODD(344–698) PM produced by in vitro
SUMOylation were incubated with Flag-VHL
produced by in vitro translation. After washing
and eluting with Flag peptide, the precipitates
were immunoblotted with ant-HIF1a (middle
panel) or anti-SUMO-1(right panel) antibodies.
(E) Mapping of VHL domain that bound to
SUMO-1-fused ODD. GST-ODD(344–698) PM
and SUMO-1-fused GST-ODD(344–698) PM
recombinant proteins were incubated with HA-VHL and its mutant produced by in vitro translation for 2 hr. The precipitates with glutathione-agarose
beads were detected by immunoblotting with ant-HA (top and right panel) or anti-HIF1a antibodies (bottom panel).
(F) HIF1a degradation induced by SENP1 silencing was VHL dependent. RCC4 or RCC4/VHL cells and SENP1-siRNA stable transfected RCC4 or
RCC4/VHL cells were treated by hypoxia (1% O2) for 4 hr as indicated. Cell lysates were detected by immunoblotting with anti-HIF1a or anti-actin
antibodies.HIF1a. As shown in Figure 6C, SUMOylation of HIF1a PM
was greatly enhanced by expression of SENP1siRNA plus
MG132 treatment (lane 4, bottom panel, Figure 6C). SU-
MOylated HIF1a from the nuclear fraction was efficiently
coprecipitated by VHL (lane 4 in top and second panels,
Figure 6C). To directly confirm the binding of VHL and SU-
MOylated HIF1a, we performed an in vitro binding assay.
As shown in Figure 6D, VHL pulled down SUMOylated
GST-ODD(344-698) PM, detected by anti-HIF1a antibody(Figure 6D, middle panel). These bands were confirmed as
SUMOylated HIF1a by anti-SUMO-1 antibody (Figure 6D,
right panel). Importantly, unmodified GST-ODD(344-698)
PM, even though presented in a much larger quantity
than SUMOylated GST-ODD(344-698) PM, could not be
coprecipitated by VHL. We further mapped the SUMO-
binding domain on VHL protein by using recombinant
SUMO-fused GST-ODD(344-698) PM to pull down
in vitro-translated VHL deletion mutants. As shown inCell 131, 584–595, November 2, 2007 ª2007 Elsevier Inc. 591
Figure 6E, SUMO-fused GST-ODDPM protein could pull
down VHL deletion mutants that contained the b domain.
However, SUMO-fused GST-ODDPM protein could not
pull down the VHL deletion mutant that only contained
the a domain. This was dependent on SUMO-1 because
GST-ODDPM could not pull down any VHL deletion mu-
tants. Interestingly, bdomain iswell documented as a sub-
strate-binding region when VHL acts as a component of
the E3 ligase complex (Ohh et al., 2000; Stebbins et al.,
1999). Taken together, these results clearly suggest that
SUMOylation of HIF1a could serve as an alternate signal
for binding to VHL in the absence of proline hydroxylation.
To directly demonstrate the role of SENP1 in VHL-de-
pendent degradation of SUMOylated HIF1a, we gener-
ated SENP1 siRNA stably transfected RCC4 and RCC4/
VHL cell lines. The expression of endogenous SENP1
was significantly decreased in these two cell lines
(Figure S8). Silencing of SENP1 markedly decreased
HIF1a expression in RCC4/VHL but not in RCC4 cells
(Figure 6F), confirming that HIF1a turnover promoted by
inactivation of SENP1 was VHL dependent.
DISCUSSION
Biological Consequence of SUMOylation
and DeSUMOylation
SUMOylation and deSUMOylation have been shown to
regulate a large number of biological processes, including
transcription, cell signaling, cell-cycle progression, and
cancer pathogenesis (Cheng et al., 2006; Yeh et al.,
2000). However, many of these studies were carried out
in cell culture systems overexpressing enzymes involved
in SUMOylation and deSUMOylation. A limited number
of studies have addressed the physiological importance
of this emerging pathway of biological regulation. For ex-
ample, knocking out the SUMO conjugation enzyme Ubc9
in mice resulted in embryonic lethality at the early post-im-
plantation stage (Nacerddine et al., 2005). Ubc9-deficient
cells showed severe defects in nuclear organization in-
cluding chromosome condensation and segregation.
This study indicates that global disruption of the SUMOy-
lation pathway is lethal in mammals. Consistent with this,
mice with an incomplete SENP1 knockout die between
E12.5 and E14.5 (Yamaguchi et al., 2005).
In the present study, we show that SENP1 plays an es-
sential role in the deconjugation of SUMOylated HIF1a.
This deconjugation has important biological consequence
as SENP1/ embryos are severely anemic, which is most
likely the cause of fetal death. This is surprising because in
an overexpression system, both SENP1 and SENP2 have
identical substrate specificity. Here, SUMOylated HIF1a is
only regulated by SENP1 but not SENP2 in vivo. Thus,
SENPs clearly perform nonredundant biological functions
in both MEF cells and animals.
Regulation of HIF1a Stability during Hypoxia
HIF1a is mainly regulated at the level of protein stability
(Huang et al., 1998; Jiang et al., 1996). During normoxia,592 Cell 131, 584–595, November 2, 2007 ª2007 Elsevier Inc.HIF1a is hydroxylated at two critical proline residues by
a family of oxygen-sensitive enzymes, prolyl 4-hydroxy-
lases (PHD) (Bruick and McKnight, 2001; Epstein et al.,
2001; Yu et al., 2001). Proline-hydoxylated HIF1a then
binds to VHL, a component of the ubiquitin E3 ligase com-
plex that consists of Cul-2, VHL, elongin B, and elongin C
(Bruick and McKnight, 2001; Ivan et al., 2001; Jaakkola
et al., 2001; Maxwell et al., 1999). Subsequently, HIF1a
is ubiquitinated and degraded by the proteasome. It was
assumed that during hypoxia, proline hydroxylation oc-
curs inefficiently, thus allowing HIF1a to escape binding
to VHL and proteasomal degradation (Figure 7). Most
studies about HIF1a stability primarily focus on the mech-
anism involving the regulation of PHD enzymatic activities
(Epstein et al., 2001; Gerald et al., 2004; Ivan et al., 2001;
Jaakkola et al., 2001; Nakayama et al., 2004). However,
a few reports have shown that there are other factors
that can regulate HIF1a stability in a VHL-independent
manner. For example, Liu et al. recently showed that
RACK1 could replace HSP90’s binding of HIF1a and tar-
get the unmodified HIF1a to the elongin C complex for
ubiquitination and degradation (Liu et al., 2007). There
are also modifications other than hydroxylation that regu-
late HIF1a stability and activity (Brahimi-Horn et al., 2005).
Our SENP1/ embryos demonstrate that a SUMOyla-
tion and deSUMOylation cycle is involved in the regulation
of HIF1a stability during hypoxia. Hypoxia induces nuclear
translocation (Kallio et al., 1998) and, as we have shown
here, SUMOylation of HIF1a, which binds to VHL in a hy-
droxyl proline-independent manner, leading to ubiquitina-
tion and proteasomal degradation (Figure 7). It should be
noted that SUMOylation is not required for hypoxia-in-
duced nuclear translocation of HIF1a (X.K. and E.T.H.Y.,
unpublished data). We currently do not know how hypoxia
Figure 7. SENP1 Regulates HIF1a Stability in Hypoxia
Hypoxia blocks the activity of PHD, preventing hydroxylation of HIF1a
and its subsequent degradation in a VHL- and ubiquitin-dependent
manner. On the other hand, hypoxia induces nuclear translocation
and SUMOylation of HIF1a, which provides an alternative signal for
VHL- and ubiquitin-dependent degradation. SENP1 stabilizes HIF1a
by removing the alternative VHL-binding signal.
induces SUMOylation of HIF1a. This may be due to an in-
crease in SUMO E3 ligase activity (X.K. and E.T.H.Y., un-
published data). SENP1, which is predominately a nuclear
protein, is well positioned to regulate the stability of HIF1a
in the nucleus by removing SUMO (Gong et al., 2000).
Unmodified HIF1a would escape VHL/proteasome-
dependent degradation to participate in the regulation
of hypoxia-responsive genes. When SENP1 is absent,
SUMOylated HIF1a will be degraded through a VHL/pro-
teasome-dependent mechanism (Figure 6). Groulx et al.
have proposed that HIF1a is degraded in the cytosol
(Groulx and Lee, 2002). However, we do not knowwhether
SUMOylated and ubiquitinated HIF1a is also degraded
in the cytosol. Further studies are required to resolve
this issue.
A previous study showed that overexpression of
SUMO-1 increased HIF1a protein level and its activity
not only under hypoxia but also in normoxia condition
(Bae et al., 2004), leading to the hypothesis that SUMOy-
lation stabilizes HIF1a. This model is inconsistent with our
results demonstrating that SUMOylation leads to the deg-
radation of HIF1a. The contrasting results from the previ-
ous study may be attributed to the overexpression of
SUMO-1 in the presence of SENP1. In the presence of
SENP1, SUMOylated HIF1a will be deconjugated and in-
deed stabilized. The SENP1 knockout mouse has enabled
us to uncover an opposite role for SUMOylation in the reg-
ulation of HIF1a.
SUMOylation Can Target a Protein for
Proteasomal Degradation
Our results provide direct evidence that SUMOylation can
induce degradation of a target protein in a proteasome-
dependent manner. It is well accepted that SUMOylation
can stabilize target proteins, as SUMO can conjugate to
the same lysine sites on target proteins as in ubiquitination
(Hay, 2005). Although ubiquitin-conjugated sites on the
HIF1a protein have not been defined precisely, the re-
ported ubiquitin-conjugated region of HIF1a indicates
that at least lysines 391 and 477, two SUMOylation sites
on the HIF1a protein, are not themajor sites for ubiquitina-
tion (Ivan et al., 2001; Masson et al., 2001; Ohh et al.,
2000). We also found that the level of HIF1a SUMOylation
correlated with the level of ubiquitination, suggesting that
SUMO conjugation of HIF1a is not on the same sites as
ubiquitination. More importantly, we identified an E3 ubiq-
uitin ligase VHL for SUMOylated HIF1a degradation. It was
previously shown that PML could be SUMOylated and
ubiquitinated when exposed to arsenic trioxide (Lalle-
mand-Breitenbach et al., 2001). However, it is not known
whether SUMOylated PML is required for binding to an
ubiquitin ligase to allow for ubiquitination and degrada-
tion. Currently, we also do not know whether SUMO-me-
diated binding of substrates to ubiquitin E3 can be gener-
alized to more SUMOylated substrates.
In conclusion, our results support a model in which SU-
MOylated HIF1a is unstable but can be stabilized when
SUMO is removed by SENP1 (Figure 7). When SENP1 isdeleted, SUMOylated HIF1a is degraded, in a VHL- and
ubiquitin/proteasome-dependent manner, resulting in de-
creased Epo production and severe fetal anemia. This
study provides evidence for the physiological role of de-
SUMOylation as demonstrated in an animal model; our
study also reveals that SUMOylation can target a protein
for ubiquitination and proteasomal degradation.
EXPERIMENTAL PROCEDURES
Generation of SENP1/ Mice
The SENP1+/ ES cell line XG001 was obtained from BayGenomics.
XG001 cells were generated by using a gene trap protocol with the
trapping construct pGT1Lxf containing the intron from the engrailed-
2 gene upstream of the gene encoding the b-galactosidase/neomy-
cin-resistance fusion protein (see http://baygenomics.ucsf.edu). The
vector was inserted into intron 8 of the SENP1 locus. A male chimeric
mouse was generated from the ES cell line. C57 BL6 mice were ob-
tained from The Jackson Laboratory.
Plasmids and Antibodies
The Epo enhancer (Epo-Luc) and the HIF1a-binding site mutant
(mEpo-Luc) were provided by Dr. H.M. Sucov. HRE-Luc was provided
by Dr. J. Yi. pGal4-VP16 and pGal4-ODD(344–698)-VP16 were pro-
vided by Dr. P.J. Ratcliffe. Flag-VHL was provided by Dr. T. Kamitani.
VHL(1–213), VHL(54–213), VHL(63–155), and VHL(156–213) were pro-
vided by Dr. M. Ohh. HA-SUMO-1, Flag-SENP1, and Flag-SENP1 cat-
alytic mutant were previously described (1, 2). RGS-HIF1a, RGS-
HIF1aK391R, RGS-HIF1aK477R, RGS-HIF1aSM (K391R, K477R),
RGS-HIF1a PM (P402A, P564A), pET-ODD(344–698)PM(p402A,
P564A), and pET-ODD(344–698)PM-SUMO1 were generated using
standard cloning procedures and PCR-based mutagenesis. We used
antibodies against Flag (M2, Sigma), HA (HA-7, Sigma), Myc (Santa
Cruz), SUMO-1 (Zymed), SUMO-2/3 (gifted from Dr. Mike Matunis),
mouse HIF1a (Novus), and human HIF1a (BD).
Histopathologic and Immunohistochemistry Analysis
Embryos were fixed in 10% buffered formalin (Sigma) and embedded
in paraffin. Five-micrometer-thick sections were stained with hema-
toxylin and eosin. For proliferation studies, the sections were stained
with Ki67-specific antibodies (Dako). Apoptotic cells were detected
in sections using the TUNEL stain (TACS TdT DAB kit, R&D).
Colony-Formation Assays
Cells were prepared from the livers of E13.5 embryos in a-MEM
(GIBCO–BRL) and counted in the presence of 3% acetic acid, which
lysed erythrocytes. Cell suspensions were mixed with MethoCult
M3334 to detect BFU-e or MethoCult M3434 to detect CFU-e (Stem-
Cell Technologies). Cells were plated in 35 mm dishes and cultured at
37C in an atmosphere containing 5%CO2. For the CFU-e assay, ben-
zidine-positive CFU-e colonies were scored on day 3. For the BFU-E
assay, benzidine-positive BFU-e colonies were scored on day 8.
Flow Cytometry
Single-cell suspensions were obtained from E13.5 wild-type and mu-
tant fetal livers. Cell suspensions were first incubated on ice with rat
anti-mouse CD16/CD32 (PharMingen) to block nonspecific binding
to Fc receptors. Subsequently, cells were incubated with rat anti-
mouse PE-conjugated anti-c-kit and anti-CD44 and FITC-conjugated
anti-CD34 and anti-Ter-119 (all from PharMingen). Appropriate isotype
control antibodies were used. Cell-surface expression of different
markers was analyzed in a Becton Dickinson FACScan using Cell-
Quest software. For the TUNEL assay, cells were stained using a
TUNEL kit from Roche and then analyzed by flow cytometry.Cell 131, 584–595, November 2, 2007 ª2007 Elsevier Inc. 593
RNA Interference
Two 21 nucleotide SENP1 siRNAs (si-1: AACTACATCTTCGTG
TACCTC; si-2: CTAAACCATCTGAATTGGCTC) were synthesized
(Dharmacon). The same sequence of the si-1-inverted orientation
was used as a nonspecific siRNA control. The SENP1 and nonspecific
siRNA oligos were inserted into a pSuppressorNeo vector (IMGENEX
Corporation) according to manufacturer’s instructions. Hep 3B cells
were transfected with the siRNA plasmid using lipofectamine 2000 (In-
vitrogen). RCC4 and RCC4/VHL (purchased from ECACC) were in-
fected by retrovirus-based SENP1si-1 virus particles produced from
pSuppressorNeo-SENP1si-1 and selected by G418. Silencing effi-
ciency of the siRNA was confirmed by performing real-time PCR (for
Hep 3B) or RT-PCR (for RCC4 and RCC4/VHL) to examine SENP1 ex-
pression. TaqMan Master Mix Reagents (Applied Biosystems) were
utilized for quantitative real-time PCR (QRT-PCR) reaction. The Taq-
Man ABI PRISM 7000 Sequence Detector System (PE Applied Biosys-
tems) was used for the analysis. Primers for SENP1 (forward: 50-
TTGGCCA GAGTGCAAATGG-30; reverse: 50-TCGGCTGTTTCTTGA
TTTTTGTAA-30) and the housekeeping 18S rRNA (ABI) were utilized.
In Vitro SUMOylation Assay
In vitro SUMOylation kit was purchased from LAE Biotech International
(Rockville, MD). The reaction was carried out at 37C for 1 hr with the
mixture including E1 (150 ng), E2 (5 mg), SUMO-1 (5 mg), ATP (2 mM),
and GST-ODD(344–698)PM (300 ng).
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures
and nine figures and can be found with this article online at http://
www.cell.com/cgi/content/full/131/3/584/DC1/.
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